GSK (NYSE:GSK) Stock Rating Upgraded by StockNews.com

GSK (NYSE:GSK) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

Several other brokerages have also weighed in on GSK. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Price Performance

Shares of NYSE GSK opened at $34.08 on Friday. GSK has a twelve month low of $32.83 and a twelve month high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The firm has a fifty day simple moving average of $35.16 and a 200 day simple moving average of $38.65. The company has a market capitalization of $70.63 billion, a PE ratio of 22.13, a P/E/G ratio of 1.54 and a beta of 0.64.

Hedge Funds Weigh In On GSK

Hedge funds have recently bought and sold shares of the company. FMR LLC grew its holdings in shares of GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC lifted its stake in GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after acquiring an additional 870,449 shares during the period. Primecap Management Co. CA boosted its holdings in GSK by 2.4% in the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock worth $607,222,000 after purchasing an additional 342,365 shares during the last quarter. Provident Trust Co. boosted its stake in shares of GSK by 1.7% in the 3rd quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock worth $161,623,000 after buying an additional 66,765 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC grew its stake in shares of GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after purchasing an additional 833,080 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.